Sarepta Therapeutics (SRPT) Research & Development (2010 - 2026)
Sarepta Therapeutics' quarterly Research & Development came in at $154.0 million in Q1 2026, down 80.09% year-on-year from $773.4 million in Q1 2025, and down 52.68% quarter-over-quarter from $325.3 million in Q4 2025.
Sarepta Therapeutics has reported Research & Development for 17 years, with the latest figure at $154.0 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 80.09% year-over-year to $154.0 million; the trailing twelve-month figure through Mar 2026 stood at $902.6 million (down 34.48% YoY), and the FY2025 full-year result was $1.5 billion, up 89.19% from the prior year.
- Research & Development for Q1 2026 stood at $154.0 million, down from $325.3 million in the prior quarter.
- The five-year high for Research & Development was $773.4 million in Q1 2025, with the low at $154.0 million in Q1 2026.
- Average Research & Development over 5 years is $249.1 million, with a median of $213.8 million recorded in 2022.
- Year-over-year, Research & Development jumped 285.96% in 2025 and plunged 80.09% in 2026.
- Tracing SRPT's Research & Development over 5 years: stood at $213.8 million in 2022, then slipped by 8.55% to $195.5 million in 2023, then gained by 2.27% to $200.0 million in 2024, then surged by 62.71% to $325.3 million in 2025, then sank by 52.68% to $154.0 million in 2026.
- The last three Research & Development figures came in at $154.0 million (Q1 2026), $325.3 million (Q4 2025), and $218.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | 153.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.96 Mn |
| Dec 31, 2025 | 325.34 Mn |
| Sep 30, 2025 | 218.89 Mn |
| Jun 30, 2025 | 204.39 Mn |
| Mar 31, 2025 | 773.45 Mn |
| Dec 31, 2024 | 199.95 Mn |
| Sep 30, 2024 | 224.48 Mn |
| Jun 30, 2024 | 179.69 Mn |
| Mar 31, 2024 | 200.40 Mn |
| Dec 31, 2023 | 195.52 Mn |
| Sep 30, 2023 | 194.30 Mn |
| Jun 30, 2023 | 241.89 Mn |
| Mar 31, 2023 | 245.68 Mn |
| Dec 31, 2022 | 213.80 Mn |
| Sep 30, 2022 | 216.71 Mn |
| Jun 30, 2022 | 252.33 Mn |
| Mar 31, 2022 | 194.25 Mn |
| Dec 31, 2021 | 197.30 Mn |
| Sep 30, 2021 | 139.12 Mn |
| Jun 30, 2021 | 239.62 Mn |
| Mar 31, 2021 | 195.15 Mn |
| Dec 31, 2020 | 207.24 Mn |
| Sep 30, 2020 | 190.44 Mn |
| Jun 30, 2020 | 188.52 Mn |
| Mar 31, 2020 | 136.14 Mn |
| Dec 31, 2019 | 223.14 Mn |
| Sep 30, 2019 | 133.95 Mn |
| Jun 30, 2019 | 113.27 Mn |
| Mar 31, 2019 | 90.55 Mn |
| Dec 31, 2018 | 146.21 Mn |
| Sep 30, 2018 | 86.58 Mn |
| Jun 30, 2018 | 122.85 Mn |
| Mar 31, 2018 | 46.20 Mn |
| Dec 31, 2017 | 44.44 Mn |
| Sep 30, 2017 | 34.24 Mn |
| Jun 30, 2017 | 58.91 Mn |
| Mar 31, 2017 | 29.12 Mn |
| Dec 31, 2016 | 70.75 Mn |
| Sep 30, 2016 | 34.35 Mn |
| Jun 30, 2016 | 44.35 Mn |
| Mar 31, 2016 | 38.83 Mn |
| Dec 31, 2015 | 41.38 Mn |
| Sep 30, 2015 | 36.67 Mn |
| Jun 30, 2015 | 29.18 Mn |
| Mar 31, 2015 | 39.17 Mn |
| Dec 31, 2014 | 30.83 Mn |
| Sep 30, 2014 | 21.85 Mn |
| Jun 30, 2014 | 20.64 Mn |
| Mar 31, 2014 | 20.91 Mn |
| Dec 31, 2013 | 25.08 Mn |
| Sep 30, 2013 | 21.09 Mn |
| Jun 30, 2013 | 12.98 Mn |
| Mar 31, 2013 | 13.76 Mn |
| Dec 31, 2012 | 12.83 Mn |
| Sep 30, 2012 | 10.91 Mn |
| Jun 30, 2012 | 13.85 Mn |
| Mar 31, 2012 | 14.81 Mn |
| Dec 31, 2011 | 18.70 Mn |
| Sep 30, 2011 | 15.61 Mn |
| Jun 30, 2011 | 17.75 Mn |
| Mar 31, 2011 | 14.80 Mn |
| Dec 31, 2010 | 13.89 Mn |
| Sep 30, 2010 | 9.06 Mn |
| Jun 30, 2010 | 6.93 Mn |